MedTrace Logo

A First-In-Human Study of ARO-033 in Adult Participants

NCT07662096 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-07-22

No results posted yet for this study

Summary

This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs).

Conditions

  • Healthy Participants

Interventions

DRUG

ARO-033

ARO-033 will be administered as a subcutaneous (SC) injection per schedule specified in the arm description.

DRUG

Placebo

Placebo matching to ARO-033 will be administered as SC injection per schedule specified in the arm description.

Sponsors & Collaborators

  • Arrowhead Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-25
Primary Completion
2027-07-18
Completion
2027-07-18
FDA Drug
Yes

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07662096 on ClinicalTrials.gov